The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma

Neoplasia

Volumn 6, Issue 5, 2004, Pages 457-467

  Lopez Barcons, Lluis A ^a   Zhang, Junhong ^b   Siriwitayawan, Gunching ^b   Burke, Thomas G ^b   Perez Soler, Roman ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b University of Kentucky   (United States)

Author keywords

Colorectal carcinoma; CT 26; DB67; Irinotecan; Liposome

Indexed keywords

7 TERT BUTYLDIMETHYLSILYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DB 67; DNA TOPOISOMERASE INHIBITOR; IRINOTECAN; LIPOSOME; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER SURGERY; COLON CARCINOMA; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFICACY; FEMALE; LIPOPHILICITY; LIVER METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN TUMOR; TUMOR VOLUME;

EID: 6944255267     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.04139     Document Type: Article

References (44)

1. Cunningham D and Findlay M (1996). The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer 29A, 2077-2079.
2. Rougier P, Paillot B, LaPlanche A, Morvan F, Seitz JF, Rekacewicz C, Laplaige P, Jacob J, Grandjowan S, Tigaud JM, Fabri MC, Luboinski M, and Ducreux M (1997). 5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer. Eur J Cancer 33, 1789-1793.
3. Pitot HC, Wender DB, O'Connel MJ, Schroeder G, Goldberg RM, Rubin J, Mailliard JA, Knost JA, Kirschling RJ, Lewitt R, and Windschitl HE (1997). Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 15, 2910-2919.
4. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson P, Carmichael J, Alakl M, Gruia G, Awad L, and Rougier P (2000). Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 25, 1041-1047.
5. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Strarkhammar H, Topham CA, Awad L, Jacques C, and Herait P (1998). Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352, 1413-1418.
6. Rougier P, Van Gutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, and Jacques C (1998). Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal carcinoma. Lancet 352, 1407-1412.
7. Liu LA (1989). DNA topoisomerase poison as antitumor drugs. Annu Rev Biochem 58, 351-375.
8. Jaxel C, Kohn KW, Wani MC, Wall ME, and Pommier Y (1989). Structure-activity of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 49, 1465-1469.
9. Mi Z and Burke TG (1994). Marked interspecies variations concerning the interactions of camptothecin with serum albumins: a frequency-domain fluorescence spectroscopic study. Biochemistry 33, 12540-12545.
10. Curran DP, Liu H, Josien H, and Ko SB (1996). Tandem radical reactions of isonitriles with 2-pyridonyl and other aryl radicals: scope and limitations, and a first generation synthesis of (racemic) camptothecin. Tetrahedron 52, 11385-11404.
11. Burke TG and Mi Z (1994). The structural basis of camptothecin interaction with human serum albumin: impact on drug stability. J Med Chem 37, 40-46.
12. Mi Z, Malak H, and Burke TG (1995). Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry 34, 13722-13728.
13. Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A, and Gandia D (1995). Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13, 210-221.
14. Kaneda N, Nagata H, Furuta T, and Yokokura T (1990). Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50, 1715-1720.
15. Houghton PJ, Steward CF, Thompson J, Santana VH, Furman WL, and Friedman HS (1998). Extending principles learned in model systems to clinical trials design. Oncology 12, 84-93.
16. Mathijssen RHJ, Vermeij J, de Jonge MJA, Booter K, Stoter G, and Sparreboom A (2002). Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol 20, 81-87.
17. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, and Ratain MJ (1998). Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101, 847-854.
18. Burke TG, Mishra AK, Wani MC, and Wall ME (1993). Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry 32, 5352-5364.
19. Tanizawa A, Fujimori A, Fujimori Y, and Pommier Y (1994). Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 86, 836-842.
20. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, and Potmesil M (1989). DNA topoisomerase I-targeted chemotherapy of human colon cancer xenografts. Science (Washington, DC) 246, 1046-1048.
21. Burke TG, Staubus AE, and Mishra AK (1992). Liposomal stabilization of camptothecin's lactone ring. J Am Chem Soc 114, 8318-8319.
22. Josien H, Bom D, Curran DP, Zheng YH, and Chou TC (1997). 7-Silylcamptothecins (Silatecans): a new family of camptothecin anti-tumor agents. Bioorg Med Chem Lett 7, 3189-3194.
23. Bom D, Curran DP, Kruszewski S, Zimmer SG, Strode JT, Kohlhangen G, Du W, Chavan AJ, Fraley KA, Bingcang AL, Latus U, Pommier Y, and Burke TG (2000). The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J Med Chem 43, 3970-3980.
24. Bom D, Curran DP, Zhang J, Zimmer SG, Bevins R, Kruszewski JN, Howe JN, Bingcang A, Latus LJ, and Burke TG (2001). The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity. J Control Release 74, 325-333.
25. Bom D, Curran DP, Chavan AJ, Kruszewski S, Zimmer SG, Fraley KA, and Burke TG (1999). Novel A,B,E-ring - modified camptothecins displaying high lipophilicity and markedly improved human blood stabilities. J Med Chem 42, 3018-3022.
26. Pollack IF, Erff M, Bom D, Burke TG, Strode BJT, and Curran DP (1999). Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo. Cancer Res 59, 4898-4905.
27. Alley MC, Scudeiro DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, and Boyd MR (1988). Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48, 589-601.
28. Li WY and Koda RT (2002). Stability of irinotecan hydrochloride in aqueous solutions. Am J Health-Syst Pharm 59, 539-544.
29. Warner DL and Burke TG (1997). Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of lactone and carboxylate forms of camptothecin anticancer drugs. J Chromatogr B 691, 161-171.
30. Thompson J, Stewart CF, and Hougton PJ (1998). Animal models for studying the action of topoisomerase I targeted drugs. Biochim Biophys Acta 1400, 301-319.
31. Bissery MC, Vrignaud P, Lavelle F, and Chabot GG (1996). Experimental anti-tumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anti-Cancer Drugs 7, 437-460.
32. Jansen WJM, Kolfschofen GM, Erkelens CAM, Van Ark-Otte J, Pinedo HB, and Boven E (1997). Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma. Int J Cancer 73, 891-896.
33. DelBino G, Lassota P, and Darzynkiewicz Z (1991). The S-phase cytotoxicity of camptothecin. Exp Cell Res 103, 27-35.
34. Houghton PJ, Cheshire PJ, Hallman JD, Lotz L, Friedman HS, Danks MK, and Houghton JA (1995). Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice xenografts of human tumors. Cancer Chemother Pharmacol 36, 393-403.
35. Poon MA, O'Connell MJ, Wiland HS, Kroog JE, Gerstrom JA, Tschetter LK, Levitt R, Kardinal CG, and Mailliard JA (1991). Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9, 1967-1972.
36. Allen TM, Hansen C, and Rutledge J (1989). Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. Biochim Biophys Acta 981, 27-35.
37. Mayhew EG, Lasic D, Babbar S, and Martin FJ (1992). Pharmacokinetics and antitumor activity of epirubicin encapsulation in long-circulating liposomes incorporating a polyethyleneglycol-derivatized phospholipid. Int J Cancer 51, 302-309.
38. 125I-5-iodo-2′- deoxyuridine. J Natl Cancer Inst 45, 773-782.
39. Guba M, Cernaianov G, Koehl G, Geissler EK, Janch KW, Anthuber M, Falk W, and Steinbauer M (2001). A primary tumor promotes dormancy of solitary tumor cells before inhibiting angiogenesis. Cancer Res 61, 5575-5579.
40. Noker PE, Lin TH, Page JG, Burke TG, Schweikart KM, and Rhie JK (2002). Pharmacokinetics of the camptothecin analog DB-67, in mice, rats, and dogs. Proc Am Assoc Cancer Res 43, S425.
41. Gabizon A and Papahadjopoulos D (1998). Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 85, 6949-6953.
42. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C, and Martin FJ (1991). Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 88, 11460-11464.
43. Allen Zhang J, Xuan T, Parmar M, Ma L, Ugwu S, Ali S, and Ahmad I (2004). Development and characterization of a novel liposome-based formulation of SN-38. Int J Pharm 270, 93-107.
44. Sadzuka Y, Hirotsu S, and Hirota S (1998). Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11. Cancer Lett 127, 99-106.